Biologic agents are designed to inhibit key pathogenic steps, providing therapeutic benefit for the treatment of psoriasis. Dermatology nurses must be prepared to integrate biologic agents into ...

Based on these observations, many new biologic therapies to treat psoriasis are now in development. These agents, developed primarily through recombinant DNA techniques, are designed to target T ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

Nevertheless, 68% of the $3.5 billion global psoriasis market is captured by biologic therapies; topical agents and conventional systemic drugs account for ∼25% and ∼7%, respectively.

For moderate to severe cases, systemic biologics work to ... together into the newer novel agents class that are indicated for all levels of severity in psoriasis. Unlike traditional topical ...

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.

Though much is still unknown about psoriasis, experts believe it could ... Treatments include phototherapy, steroids, topicals, and newer biologic agents which suppress the immune response.

A study found patients treated with interleukin inhibitors did not experience a difference in the rates of major adverse ...

A new study finds no significant differences in cardiovascular and thromboembolic risks among biologics for psoriasis or ...

Immunosuppressive agents prevent an effective immune ... but they still recommend vaccination. People with psoriasis should continue their current biologic or immunosuppressive therapy when ...

These findings may offer more personalized treatment and prevention recommendations for patients with psoriasis.